- Home
- CHY vs TBPH Comparison
CHY vs TBPH Comparison
Compare CHY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | TBPH |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.9M | 1.0B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CHY | TBPH |
|---|---|---|
| Price | $10.80 | $15.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.80 |
| AVG Volume (30 Days) | 177.8K | ★ 837.4K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.36 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.00 | $7.90 |
| 52 Week High | $12.12 | $21.03 |
Technical Indicators
Market Signals| Indicator | CHY | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 28.07 | 44.20 |
| Support Level | $10.72 | $13.41 |
| Resistance Level | $11.08 | $15.22 |
| Average True Range (ATR) | 0.23 | 0.41 |
| MACD | -0.06 | 0.31 |
| Stochastic Oscillator | 2.82 | 71.06 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).